Former FDA Deputy Director and Talecris executive adds extensive
clinical, regulatory and manufacturing experience to Company's Board
MONTREAL, Oct. 1 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX: HAE) announced today the appointment of Thomas J. Lynch, J.D., Ph.D. to the Company's Board of Directors. Dr. Lynch, former Deputy Director, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), currently serves as Senior Vice President Compliance, Regulatory Affairs and Public Policy for Talecris Biotherapeutics.
"Dr. Lynch brings extensive clinical, regulatory and manufacturing experience in the area of blood products and a broad strategic perspective to our Board of Directors. We are pleased to welcome him as an independent director," said Joseph Galli, Haemacure's Chairman and Chief Executive Officer. "Thomas' distinguished background and relevant expertise will be a valuable addition to our Board as we continue to make progress toward initiating a pivotal Phase II/III clinical trial for our lead product candidate, Hemaseel(R)HMN (fibrin sealant), for biosurgical hemostasis" concluded Mr. Galli.
From 2003-2005, Dr. Lynch served as Vice President, Regulatory Affairs and Quality Assurance at CryoLife, Inc., a manufacturer of medical tissues, heart valves and oncology drugs, where he was responsible for, among other things, ensuring compliance with domestic and international laws, regulations, governing the design, manufacture, and distribution of medical devices, biological products and human tissues. Prior to joining CryoLife, Dr. Lynch served as Senior Vice President, Regulatory Affairs and Quality Assurance at Clearant Inc., a biotechnology company developing pathogen inactivation technology for the biological products market. Dr. Lynch also served as Deputy Director, Division of Hematology, Office of Blood Research and Review, CBER at the FDA, a forty five-member Division engaged in research and regulatory activities related to investigational new drugs and licensing of transfusable blood components, purified plasma-derived proteins and their recombinant analogues.
Prior to the FDA, Dr. Lynch has had about 15 years experience as a research scientist in various capacities in the public, academic and private sectors; his primary scientific interests have been in the areas of protein chemistry and enzymology.
Dr. Lynch received his Bachelor of Arts degree in biology from American International College and his Masters in biology from Clark University. Dr. Lynch received his Ph.D. in biology from Wayne State University and his J.D. from Georgetown University Law Center, where he graduated cum laude.
Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first half of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on the use of its fibrin sealant in adhesion prevention, aesthetics, combination with biomaterials, drug delivery, regenerative medicine, skin graft fixation for burn injuries and wound management. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure is headquartered in Montreal, Quebec and operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.
Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.
|SOURCE HAEMACURE CORPORATION|
Copyright©2008 PR Newswire.
All rights reserved